BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 19521065)

  • 21. An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
    Harris MT; Rosenthal MA; Ashley DL; Cher L
    J Clin Neurosci; 2001 Jul; 8(4):325-7. PubMed ID: 11437571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
    Kesari S; Schiff D; Drappatz J; LaFrankie D; Doherty L; Macklin EA; Muzikansky A; Santagata S; Ligon KL; Norden AD; Ciampa A; Bradshaw J; Levy B; Radakovic G; Ramakrishna N; Black PM; Wen PY
    Clin Cancer Res; 2009 Jan; 15(1):330-7. PubMed ID: 19118062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Capecitabine and Temozolomide as a Promising Therapy for Advanced Thymic Atypical Carcinoid.
    Wang X; Li Y; Duan J; Chen Y; Yuan B; Qi Z; Tan H
    Oncologist; 2019 Jun; 24(6):798-802. PubMed ID: 30413666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas.
    Kuo DJ; Weiner HL; Wisoff J; Miller DC; Knopp EA; Finlay JL
    J Pediatr Hematol Oncol; 2003 May; 25(5):372-8. PubMed ID: 12759623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study.
    Combs SE; Gutwein S; Schulz-Ertner D; van Kampen M; Thilmann C; Edler L; Wannenmacher MM; Debus J
    Strahlenther Onkol; 2005 Jun; 181(6):372-7. PubMed ID: 15925979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.
    Trent JC; Beach J; Burgess MA; Papadopolous N; Chen LL; Benjamin RS; Patel SR
    Cancer; 2003 Dec; 98(12):2693-9. PubMed ID: 14669291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
    de Mestier L; Walter T; Brixi H; Evrard C; Legoux JL; de Boissieu P; Hentic O; Cros J; Hammel P; Tougeron D; Lombard-Bohas C; Rebours V; Ruszniewski P; Cadiot G
    Neuroendocrinology; 2019; 108(4):343-353. PubMed ID: 30759445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
    Athanassiou H; Synodinou M; Maragoudakis E; Paraskevaidis M; Verigos C; Misailidou D; Antonadou D; Saris G; Beroukas K; Karageorgis P
    J Clin Oncol; 2005 Apr; 23(10):2372-7. PubMed ID: 15800329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of two-weekly temozolomide in patients with high-grade gliomas.
    Wong S; Rosenthal MA; Dowling A; Jennens R; Woods AM; Ashley D; Cher L
    J Clin Neurosci; 2006 Jan; 13(1):18-22. PubMed ID: 16356721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment.
    Yaman E; Buyukberber S; Uner A; Coskun U; Akmansu M; Benekli M; Yamac D; Ozturk B; Kaya AO; Yildiz R; Ozkan S; Gunel N
    Onkologie; 2008 Jun; 31(6):309-13. PubMed ID: 18547971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
    Nicholson HS; Kretschmar CS; Krailo M; Bernstein M; Kadota R; Fort D; Friedman H; Harris MB; Tedeschi-Blok N; Mazewski C; Sato J; Reaman GH
    Cancer; 2007 Oct; 110(7):1542-50. PubMed ID: 17705175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors.
    Mueller D; Krug S; Majumder M; Rinke A; Gress TM
    BMC Cancer; 2016 Aug; 16():645. PubMed ID: 27538897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of temozolomide using an extended continuous oral schedule.
    Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
    Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
    Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
    J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
    Wick A; Felsberg J; Steinbach JP; Herrlinger U; Platten M; Blaschke B; Meyermann R; Reifenberger G; Weller M; Wick W
    J Clin Oncol; 2007 Aug; 25(22):3357-61. PubMed ID: 17664483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
    Chang SM; Prados MD; Yung WK; Fine H; Junck L; Greenberg H; Robins HI; Mehta M; Fink KL; Jaeckle KA; Kuhn J; Hess K; Schold C
    Cancer; 2004 Apr; 100(8):1712-6. PubMed ID: 15073861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of temozolomide in patients with progressive low-grade glioma.
    Quinn JA; Reardon DA; Friedman AH; Rich JN; Sampson JH; Provenzale JM; McLendon RE; Gururangan S; Bigner DD; Herndon JE; Avgeropoulos N; Finlay J; Tourt-Uhlig S; Affronti ML; Evans B; Stafford-Fox V; Zaknoen S; Friedman HS
    J Clin Oncol; 2003 Feb; 21(4):646-51. PubMed ID: 12586801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.
    Lashford LS; Thiesse P; Jouvet A; Jaspan T; Couanet D; Griffiths PD; Doz F; Ironside J; Robson K; Hobson R; Dugan M; Pearson AD; Vassal G; Frappaz D;
    J Clin Oncol; 2002 Dec; 20(24):4684-91. PubMed ID: 12488414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study.
    Giorgio CG; Giuffrida D; Pappalardo A; Russo A; Santini D; Salice P; Blanco G; Castorina S; Failla G; Bordonaro R
    Lung Cancer; 2005 Nov; 50(2):247-54. PubMed ID: 16039010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases.
    Christodoulou C; Bafaloukos D; Kosmidis P; Samantas E; Bamias A; Papakostas P; Karabelis A; Bacoyiannis C; Skarlos DV;
    Ann Oncol; 2001 Feb; 12(2):249-54. PubMed ID: 11300333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.